在感染性眼科疾病的诊疗过程中，商品化眼用制剂尚未能完全满足临床治疗需求，在治疗一些现有眼用制剂未能满足治疗需求的感染性眼病时，需要采用临时配制的滴眼液来进行治疗。由于目前国内尚无临时配制滴眼液的规范或者标准，广东省药学会眼科药学专家委员会组织相关专家讨论，制定了治疗感染性眼部疾病临时配制滴眼液专家共识，以提升临床所需临配制剂的可及性，供国内从事临时配制滴眼液相关工作的同行借鉴。

Commercial eye drops fail to fully meet the therapeutic requirements for infectious ocular diseases. When treating certain infectious ocular diseases where existing ophthalmic preparations are inadequate, extemporaneously prepared eye drops become necessary. Given the absence of regulations or standards for extemporaneously prepared eye drops in China, the Ophthalmic Pharmacy Expert Committee of the Guangdong Pharmaceutical Association organized relevant experts relevant experts to establish a standard for the extemporaneous preparation of eye drops after rigorous discussions. This initiative aims to enhance the accessibility of extemporaneously prepared eye drops and provide reference for ophthalmologists, pharmacy workers, and users of ophthalmic extemporaneously preparations.

目的: 探讨白内障手术患者围手术期非甾体抗炎药（non-steroidal anti-inflammatory drugs, NSAIDs）滴眼液应用的合理性，为优化临床用药方案提供依据。方法：采用回顾性研究方法，分析郑州市第二人民医院2024年100例（100眼）行白内障超声乳化并人工晶状体植入手术患者的临床数据，依据药品说明书、《我国白内障围手术期非感染性炎症反应防治专家共识(2015年)》《中国成人白内障摘除手术指南（2023年）》《中国激光角膜屈光手术围手术期用药专家共识（2024年）》等指南/共识制定评价标准，评价NSAIDs滴眼液的用药频次、疗程及术前预防性抗炎处理的规范性。结果：35%的病例存在用药不合理，共发现88项问题，包括用药频次错误（7.96%）、超疗程（22.72%）及术前用药不当（69.32%）。其中，65%糖尿病患者术前未启动NSAIDs预处理，41%非糖尿病患者术前1 d使用NSAIDs；溴芬酸钠滴眼液疗程超过10天者占20.45%，可能增加肝损伤风险。结论：医疗机构应采取积极有效措施，如制定个体化用药方案、加强合理用药培训、开展专项处方点评等，切实促进NSAIDs滴眼液在白内障手术患者围手术期的合理使用，保障患者的用药安全与治疗效果，提高医疗服务质量和患者满意度。

Objective: To investigate the rationality of perioperative application of non-steroidal anti-inflammatory drugs (NSAIDs) eye drops in patients undergoing cataract surgery, thereby providing evidence for optimizing clinical medication protocols. Methods: A retrospective study method was used to analyse the clinical data of 100 patients (100 eyes) who underwent cataract ultrasonoemulsification with IOL implantation in 2024 at the Second People's Hospital of Zhengzhou City, and the evaluation criteria were developed based on the instructions of the medication, the Chinese expert consensus on prevention and management of non-infectious inflammatory responses in the perioperative period of cataract surgery (2015), the Chinese guideline for cataract surgery in adults (2023), and the Chinese expert consensus on the perioperative medication in laser corneal refractive surgery(2024)" and other guidelines/consensus to develop evaluation criteria to evaluate the standardisation of NSAIDs eye drops in terms of frequency of dosing, duration of treatment, and preoperative prophylactic anti-inflammatory treatment. Results: Irrational medication use was identified in 35% of cases, with a total of 88 issues categorized as follows: incorrect dosage frequency (7.96%), prolonged treatment duration (22.72%), and inappropriate preoperative medication (69.32%). Notably, 65% of diabetic patients failed to initiate NSAIDs pretreatment preoperatively as recommended by guidelines, while 41% of non-diabetic patients received NSAIDs one day before surgery. Prolonged use of bromfenac eye drops (>10 days) was observed in 20.45% of cases, potentially increasing the risk of liver injury. Conclusions: Medical institutions should take active and effective measures, such as formulating individualised medication plans, strengthening training on rational use of medication, and carrying out special prescription reviews, etc., to effectively promote the rational use of NSAIDs eye drops in the perioperative period of patients undergoing cataract surgery, to safeguard the safety of patients' use of medication and therapeutic efficacy, and to improve the quality of healthcare services and patients' satisfaction.

目的：通过为青光眼患者提供安全、有效、经济、合理的规范化药学服务，探讨药物重整在青光眼患者中的临床应用价值，并评估药物重整服务在眼科专科用药方面的可行性。方法：采用前瞻性研究设计，纳入武汉大学附属爱尔眼科医院2023年8月-2024年1月青光眼住院患者308例, 临床药师通过收集用药史、医嘱审核、用药偏差纠正、用药教育等多种方式实施药物重整服务。结果：在308例患者中，104例患者存在需重整的用药问题，重整率为33.8%，重整医嘱共198条，在这些重整医嘱中，用药依从性问题占57.0%，用药安全性问题占18.1%，用药差错占24.9%。经过药物重整，患者用药依从性提升至95.1%(χ²=27.210，P<0.05)，安全性问题降至1.3%(χ²=22.565，P<0.05)，用药差错率降至1.9%(χ²=26.251，P<0.05)。结论：药物重整可提高青光眼患者的用药合理性及依从性，是保障患者用药安全、合理的有效药学服务手段。

Objective: To introduce medication reconciliation (MR) services for glaucoma patients, with the aim of delivering safe, effective, and cost-effective pharmaceutical care. This study also evaluates the clinical value of MR in glaucoma management and assesses its feasibility within ophthalmic specialized medication practices. Methods: In this prospective study, 308 hospitalized glaucoma patients were enrolled between August 2023 and January 2024. Clinical pharmacists conducted medication reconciliation using standardized procedures, which encompassed comprehensive medication history collection, medication order review, correction of discrepancies, and structured discharge counseling. Results: Among the 308 patients, MR interventions was required in 104 cases (33.80%), identifying 198 medication related issues. Of these, 57.0% pertained to medication adherence problems, 18.1% involved medication safety concerns, and 24.9% related to medication appropriateness. Following medication reconciliation, medication adherence improved to 95.1% (χ²=27.210, P<0.05), the incidence of adverse drug reactions declined to 1.3% (χ²=22.565, P<0.05), and medication appropriateness issues decreased to 1.9% (χ²=26.251, P<0.05). Conclusions: MR significantly enhances medication appropriateness and adherence in glaucoma management. This evidence-based pharmaceutical care model effectively ensures medication safety and therapeutic efficacy, offering practical insights for extending MR to other chronic ophthalmic conditions.

目的：调查眼科万古霉素使用情况，并对超说明书用药进行评价，为临床提供参考。方法 ：采用回顾性分析法，选取郑州市第二人民医院2022年1月1日—2024年12月眼科使用万古霉素的159例住院患者为研究对象，对患者基本信息、万古霉素的使用情况、微生物送检情况及超说明书用药情况等进行评价分析。结果：159例患者中男性占比76.1%，主要分布在眼底病病区，致病因素主要为眼外伤（102/159，64.15%），其次为手术源性（36/159，22.64%）。给药途径主要为玻璃体腔注射，以治疗用药为主，多联合头孢他啶治疗眼内感染。病原菌送检率为75.47%，标本检出率为35.07%。其中革兰阳性菌33例，占80.49%，主要为表皮葡萄球菌；革兰阴性菌5例，占12.20%，有大肠埃希菌、铜绿假单胞菌等；真菌4例，占9.76%，主要为曲霉菌。超说明书用药包括玻璃体腔注射、眼内灌洗及超适应证用于眼内炎的预防。玻璃体腔注射超说明书用药推荐等级及证据强度高于眼内灌洗和超适应证。结论 ：万古霉素在眼科临床应用广泛，应严格掌握适应证和用法用量。对于超说明书用药，应在充分评估其合理性和安全性后谨慎使用。本研究对万古霉素的规范化使用及药品说明书修订和个体化治疗具有重要的临床价值和现实意义。

Objective: To investigate the use of vancomycin in ophthalmology department and evaluate its off-label drug use, thereby providing references for clinical practice. Methods: A retrospective analysis was conducted, selecting 159 inpatients who received vancomycin treatment in the Department of Ophthalmology of our hospital from January 1, 2022 to December 31, 2024. The basic information of the patients, details of vancomycin, microbial testing results, and off-label drug use were evaluated and analyzed. Results: Among the 159 patients, male patients accounted for 76.1%, and there were mainly distributed in the fundus disease area. The primary pathogenic factor was ocular trauma (102/159,64.15%), followed by surgical causes (36/159,22.64%). The main route of vancomycin administration was intravitreal injection, primarily for therapeutic purposes. It was often combined with ceftazidime to treat intraocular infections. The submission rate of pathogenic bacteria was 75.47%, and the specimen detection rate was 35.07%. There were 33 cases of gram-positive bacteria, accounting for 80.49%, mainly Staphylococcus epidermidis; 5 cases of gram-negative bacteria, accounting for 12.20%, including Escherichia coli, Pseudomonas aeruginosa, etc.; and 4 cases of fungi, accounting for 9.76%, mainly Aspergillus. Off-label drug use included intravitreal injections, intraocular lavage, and the use of drugs highly suitable for the preventing endophthalmitis. Endogenous infections were mainly caused by gram-negative bacteria. The evidence-based medicine support for vancomycin intravitreal injection in the treatment of endophthalmitis is strong. The recommended grade and evidence strength of off-label use of intravitreal injection are higher than those of intraocular lavage and off-label use. Conclusions: Vancomycin is widely used in ophthalmology, and its indications, usage, and dosage should be strictly controlled. Off-label drug use should be used with caution after a comprehensive evaluation of its rationality and safety. This study holds significant clinical value and practical significance for the standardized use of vancomycin, the revision of drug instructions, and individualized treatment.

目的：分析我院2023—2024年眼科门诊处方用药情况，为提高医院眼科门诊的合理用药水平，优化处方前置审核规则提供依据，加强对药品合理使用的管控手段。方法：使用HYGEA合理用药平台，筛选2023年6月—2024年12月眼科门诊相关处方信息，包括药品使用排名和不合理处方条目，对不合理处方项目进行分类绘制帕累托图，并按照问题条目占比排序并分析主要因素、次要因素和一般因素。最终以设置给药途径为干预手段场景为例，评价合理用药平台对眼科门诊处方合格率的改善情况。 结果：按条件检索，共筛选眼科门诊55 623张处方，不合理处方条目37 760条，2023年度和2024年度发生率分别为43.32%和45.43%；绘制帕累托图结果显示，2023年影响处方合格率的主要因素为适应证规则，一般因素为给药途径、剂量限制、疗程限制和特殊人群；2024年影响处方合格率的主要因素为适应证规则，次要因素为重复用药，一般因素为给药途径、疗程限制、剂量限制、特殊人群、禁忌证和相互作用；通过干预给药途径设置规则后，不合格率从20.11%减少至2.53%，提高了处方合格率（P<0.001）。结论：合理用药平台可以通过设置规则，显著减少开具处方的错误，提高处方合格率。

Objective: To analyze prescription drug use in the ophthalmology clinic of our hospital from 2023-2024 ,promote rational drug use in the ophthalmology outpatient department  provide a basis for optimizing pre-prescription review rules, and strengthen rational drug use management. Methods: By utilizing the HYGEA rational drug use platform, we screened prescription data from the ophthalmology outpatient department spanning from June 2023 to December 2024. This data encompassed drug usage rankings and items related to irrational prescriptions. We categorized the irrational items and constructed a Pareto chart to rank and analyze the primary, secondary, and general contributing factors. Taking the intervention scenario of adjusting administration route settings as an example, we evaluated the platform's impact on enhancing prescription compliance rates. Results: A total of 55,623 ophthalmology outpatient prescriptions were screened, revealing 37,760 irrational prescriptions. This irrational prescription rates were 43.32% in 2023 and 45.43% in 2024. Pareto analysis revealed that in 2023, the main factor influencing prescription compliance was indication rules, while general factors included administration route, dosage limits, treatment duration limits, and special populations. In 2024, indication rules still constituted the primary factor, with duplicate prescriptions emerging as secondary factors. General factors encompassed administration route, treatment duration limits, dosage limits, special populations, contraindications, and drug interactions. After implementing intervention rules for administration routes, the unreasonable rate dropped from 20.11% to 2.53%. This significantly rectified erroneous administration routes and improved prescription compliance (P < 0.001). Conclusions: The rational drug use platform can significantly reduce prescription errors and enhance prescription compliance through rule-based interventions.

目的：调查神经眼科用药现状，并对其超说明书用药进行评价，探索科学有效的管理策略，为神经眼科的临床合理用药提供参考。方法：随机抽取2023年7—12月郑州市第二人民医院神经眼科处方，依据国家药品监督管理局核准的药品说明书、美国食品药品监督管理局(Food and Drug Administration, FDA)说明书及UpToDate、Micromedex等循证医学数据库证据判断超说明书用药类型，并对其进行分类(包括超适应证、超剂量、超疗程、超给药途径等)。同时基于Thomson分级理论建立三级评价标准，分别为A级(高证据等级，仅需口头告知)，B级(中证据等级，需在病历或病程中详细记录)，C级(低证据等级，须患者签署书面知情同意书)。通过处方前置审核系统干预，对未纳入评价标准的超说明书用药进行实时拦截与分级警示，比较2023年下半年(干预前)与2024年下半年(干预后)超说明书用药处方的不合理率变化。 结果：干预前共抽取超说明书处方370张，超说明书类型主要为超适应证、超给药途径和超剂量及次。干预后，共抽取超说明书用药560张，超说明书用药不合理率从9.2%(34/370)降至2.9%(16/560)。结论：神经眼科超说明书用药普遍，主要源于视神经炎、缺血性视神经病变等复杂疾病的治疗需求与药品审批滞后之间的矛盾。基于循证医学证据构建分级管理体系，结合信息化实时干预，可有效规范超说明书用药行为，降低医疗风险。

Objective: To investigate the current status of medication use in neuro-ophthalmology, evaluate off-label drug use, and explore scientific and effective management strategies, providing references for rational drug use in neuro-ophthalmology clinical practice. Methods: We Randomly selected neuro-ophthalmology prescriptions from July to December 2023 in our hospital. By refering to the drug instructions approved by the National Medical Products Administration, FDA instructions, and evidence from evidence-based medical databases such as UpToDate and Micromedex, we identified and classified the types of off-label drug use, including off-label indications, off-label doses, off-label courses, off-label administration routes, among others. Simultaneously, based on the Thomson classification theory, we established a threelevel evaluation standard: Level A (high evidence level, requiring only oral notification); Level B (medium evidence level, necessitating detailed records in the medical record or medical course); Level C (low evidence level, demanding patients sign a written informed consent form). Through the intervention of pre-prescription review system, we carried out real-time interception and classification warnings for off-label drug use not covered in the evaluation standards. We then compared the changes in the unreasonable rate of off-label drug use prescriptions from the second half of 2023 (before intervention) to the second half of 2024 (after intervention). Results: Before the intervention, a total of 1852 prescriptions were selected, with the proportion of off-label drug use at 19.98% (370 prescriptions), primarily involving off-label indications (90.27%). After the intervention, the unreasonable rate of off-label drug use decreased from 9.2% (34/370) to 2.9% (16/560). Conclusions: Off-label drug use is prevalent in neuro-ophthalmology, mainly due to the conflict between the treatment requirements for complex diseases such as optic neuritis and ischemic optic neuropathy and the delay in drug approval. By constructing a hierarchical management system based on evidence-based medical evidence and combing it with real-time information-based intervention, we can effectively regulate off-label drug use behavior and reduce medical risks.

目的：通过前房注射亚硒酸钠溶液建立新西兰兔硒性白内障模型，并评估验证其在药效试验中的应用。方法：采用前房注射10 mmol/L亚硒酸钠溶液(0.1 mL/只)对动物右眼进行造模，于造模第3天根据晶状体混浊度评分选取成模动物分为模型组、吡诺克辛滴眼液(pirenoxine sodium eye drops, PSED)0.05 mg/mL组，以模型组动物左眼作为空白组，每组8只眼；分组后对各组动物眼进行滴眼给药，50 µL/眼/次，3 次/天，连续给药17 d。于给药前、给药第7、17天进行裂隙灯检查拍照在体评估晶状体混浊度，末次给药后完整分离各组动物晶状体，体外评估晶状体透明度，然后将各组动物晶状体匀浆，用于过氧化物酶(peroxidase, POD)及谷胱甘肽过氧化物酶(glutathione peroxidase, GSH-Px)活力测定。结果：与空白组相比，模型组给药前、给药第7、17天晶状体混浊度评分均升高，给药结束后晶状体透明度评分升高，晶状体中GSH-PX和POD活力均降低；与模型组相比，PSED 0.05 mg/mL组给药17d晶状体混浊度和透明度评分均降低，晶状体中GSH-PX活力升高，POD无变化。结论：前房注射亚硒酸钠溶液可诱导新西兰兔发展出稳定的白内障模型症状，适用于药物药效作用的评价。

Objective: To establish a selenium-induced cataract model in New Zealand rabbits by anterior chamber injection of sodium selenite solution and evaluate and verify its application in pharmacodynamic trials. Methods: The right eyes of the animals were modeled by anterior chamber injection of 10 mmol/L sodium selenite solution (0.1 mL per animal). On the third day of modeling, the modeled animals were selected and divided into the model group and the pirenoxine sodium eye drops (PSED) 0.05 mg/mL group based on the lens turbidity score. The left eyes of the animals in the model group were taken as the blank group, with 8 eyes in each group. After grouping, eye drops were administered to the eyes of each group of animals. The dosage was 50 µL per eye each time, three times a day, for 17 consecutive days. Slit lamp examination and photography were conducted on the 7th and 17th days of administration to evaluate the turbidity of the lenses in vivo. After the last administration, the lenses of each group of animals were completely isolated, and the transparency of the lenses was evaluated in vitro. Then, the lenses of each group of animals were homogenized. It is used for the determination of peroxidase (POD) and glutathione peroxidase (GSH-Px) activities. Results: Compared with the blank group, the lens turbidity scores of the model group were significantly increased before administration, on the 7th and 17th days of administration, the lens transparency scores were significantly increased after the end of administration, and the activities of GSH-PX and POD in the lens were significantly decreased. Compared with the model group, the scores of lens turbidity and transparency in the PSED 0.05 mg/mL group and 17 days after administration were significantly decreased, the activity of GSH-PX in the lens was significantly increased, and there was no change in POD. Conclusions: Anterior chamber injection of sodium selenite solution can induce the development of stable cataract model symptoms in New Zealand rabbits and is suitable for the screening and evaluation of drug efficacy.

白内障是全球第一大致盲眼病，表现为由多种原因导致的晶状体病变，进而出现视物模糊的现象，严重者会进一步丧失视力。白内障的类型较多，发病机制尚未完全阐释清楚，氧化应激是目前公认的主要影响因素。药物治疗一直是白内障患者临床治疗的一大难题，目前市面上还没有能够真正逆转白内障的药物，现有的药物仅能在一定程度上缓解白内障的进展。手术治疗仍是现阶段唯一有效的治疗方式，但经济因素和术后并发症的风险限制了部分患者通过手术恢复视力。白内障的治疗一直是眼科领域研究的重点，目前研究主要集中在两个战略方向上：优化手术技术并结合更优的围术期药物治疗方案以减少并发症，以及对疾病机制进行基础研究以促进新靶点药物的发现。有效的药物治疗一直是目前临床治疗的一大缺口，近年来研究者在白内障机制探索和新药研发上取得了显著进展，多个新的治疗靶点以及相关治疗药物不断被发现，但相关药物真正进入临床还面临着诸多挑战。文章主要从机制研究进展、药物治疗现状和前景较好的白内障药物临床研究进展等进行综述，旨在为新的白内障药物研发提供最新的参考。

Cataracts remain the leading cause of blindness globally. They manifest as lens opacification triggered by various factors, leading to blurred vision. In severe cases, patients may eventually lose their vision entirely. There are many types of cataracts, and their pathogenesis has not been fully clarified. Currently, oxidative stress is widely acknowledged as the primary influencing factor. Pharmacological intervention remains a significant clinical challenge in cataract management. At present, there are no drugs on the market capable of truly reversing cataracts; existing medications can only alleviate the progression of the condition to a certain extent. Surgical treatment remains the only effective approach at this stage. However, economic limitations and the risks of postoperative complications hinder its accessibility for certain patient groups. The treatment of cataracts has consistently been a research hotspot in the field of ophthalmology. Current research mainly centers on two strategic approaches: optimizing surgical techniques alongside improved perioperative pharmaceutical regimens to minimize complications, and conducting basic researches on disease mechanisms to facilitate drug discovery. Effective drug treatment has long been a major gap in current clinical treatment. In recent years, significant progress has been achieved in the exploration of cataract mechanisms and the development of new drugs. Despite the remarkable advancements in uncovering cataract pathogenesis and identifying novel therapeutic targets in recent years, substantial challenges remain in translating these discoveries into clinically applicable medications. This article reviews the progress in mechanism research, the current state of pharmacological interventions, and the clinical research developments of several promising cataract drugs, aiming to provide the latest reference for the research and development of new cataract drugs.

眼表是统一整体，依靠泪液、细胞、神经及免疫等综合因素维持平衡，某个或多个因素的失衡会造成眼表出现一系列连锁反应，导致眼表疾病，影响个体生活质量。近年来，越来越多研究围绕细胞能量代谢与多种疾病的发生、发展和治疗进行，纠正细胞能量代谢的异常是治疗此类疾病的重要思路。小牛血去蛋白提取物从发现并应用至今已有60多年历史，具有良好的组织修复作用和安全性。作为经典的能量补充修复剂，小牛血去蛋白提取物眼用制剂以特定工艺去蛋白处理的小牛血液提取物作为其主要有效成分，具有多重作用机制，在不同严重程度的角膜损伤、干眼症、眼烧伤等多种眼表疾病的治疗方面展现出良好的效果。文章就小牛血去蛋白提取物眼用制剂的制备工艺、作用机制、安全性以及临床应用等进行综述，旨在系统梳理小牛血去蛋白提取物眼用制剂的临床应用价值，并为其在未来的实验研究以及在眼表疾病的进一步实践应用提供科学依据和参考价值。

The ocular surface is an integrated entity maintained in equilibrium by a complex interplay of factors, including tears, cellular components, neural mechanisms, and immunological processes. Disruption of one or multiple factors can precipitate a cascade of reactions on the ocular surface, leading to ocular surface diseases and consequently affecting an individual's quality of life. In recent years, more researches have focused on the relationship between cellular energy metabolism and the occurrence, development, as well as treatment of a wide range of diseases. To treat such diseases, correcting the abnormality of cellular energy metabolism is an important idea. Deproteinized calf blood extract ophthalmic preparation has been discovered and applied over sixty years, demonstrating excellent tissue repairment and safety. As a classic energy supplement, deproteinized calf blood extract ophthalmic preparation process with specific technique involving deproteinized calf blood extract as its main active ingredient and showing significant effects in the treatment of various ocular surface diseases such as corneal injuries, dry eye syndrome, and ocular burns. This article summarized the preparation process, mechanism of action, safety, and clinical applications of deproteinized calf blood extract ophthalmic preparation. It aims to systematically organize the clinical utility of deproteinized calf blood extract ophthalmic preparation and provide scientific evidence and reference value for future research and practical applications in the treatment of ocular surface diseases.

全球范围内，肥胖或超重问题持续加剧，据《2024年世界肥胖报告》及近期数据，预计2035年受超重或肥胖影响的成年人将达33亿，我国成人肥胖或超重患病率已超50%且呈上升趋势。肥胖会增加2型糖尿病、心血管疾病等多种疾病风险，减轻5%～15%体重可改善相关并发症，因此减重关注度日益提升，除运动和饮食控制外，减重药物与手术等手段不断涌现。然而减重药物在减轻体质量（体重）的同时，其潜在的危害不容忽视，有研究表明减重药物可对眼部产生不良影响：导致眼压升高使患者出现眼睛疼痛、视力模糊的症状；影响眼部血液循环和营养供应，发生炎症感染；出现眼睛疲劳干涩，对糖尿病性视网膜病变产生影响等。本文聚焦目前主流的三类减重药物——非中枢性减重药物（以脂肪酶抑制剂为代表）、中枢性减重药物（含拟儿茶酚胺类制剂和5-羟色胺受体激动剂）、兼有减重效果的降糖药物（包括GLP-1RA、GLP-1/GIP双受体激动剂、二甲双胍等），详细论述其应用及对眼部的不良反应。同时，也提及部分药物可能对眼部产生的益处，如二甲双胍、GLP-1RA或对青光眼、糖尿病视网膜病变有潜在保护作用。本文旨在为用药人群、相关医护及从业人员提供理论指导，强调使用减重药物时需警惕眼部风险，平衡疗效与安全性。

Globally, the problem of obesity or overweight continues to intensify. According to the "2024 World Obesity Report" and recent data, it is estimated that by 2035, the number of adults affected by overweight or obesity will reach 3.3 billion. In China, the prevalence of obesity or overweight among adults has exceeded 50% and is on the rise. Obesity increases the risk of various diseases such as type 2 diabetes and cardiovascular diseases. Reducing body weight by 5% to 15% can improve related complications. Therefore, the focus on weight loss is increasing. Besides exercise and dietary control, weight loss drugs and surgeries are constantly emerging. However, while weight loss drugs can reduce body weight, their potential harms should not be ignored. Studies have shown that weight loss drugs can have adverse effects on the eyes: causing increased intraocular pressure, leading to symptoms such as eye pain and blurred vision; affecting blood circulation and nutrient supply to the eyes, resulting in inflammation and infection; causing eye fatigue and dryness, and having an impact on diabetic retinopathy, etc. This article focuses on the three main types of weight loss drugs currently available - non-central weight loss drugs (represented by fat enzyme inhibitors), central weight loss drugs (including catecholamine-like preparations and 5-hydroxytryptamine receptor agonists), and hypoglycemic drugs with weight loss effects (including GLP-1RA, GLP-1/GIP dual receptor agonists, metformin, etc.), and elaborates on their applications and adverse reactions to the eyes. At the same time, it also mentions the potential benefits that some drugs may have on the eyes, such as metformin and GLP-1RA, which may have a protective effect on glaucoma and diabetic retinopathy. This article aims to provide theoretical guidance for drug users, related medical staff, and professionals, emphasizing the need to be vigilant about eye risks when using weight loss drugs and to balance efficacy and safety.